These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38621856)

  • 1. Finding the best subgroup with differential treatment effect with multiple outcomes.
    Zhao B; Fine J; Ivanova A
    Stat Med; 2024 Jun; 43(13):2487-2500. PubMed ID: 38621856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival data.
    Zhang P; Ma J; Chen X; Shentu Y
    Stat Med; 2020 Dec; 39(28):4133-4146. PubMed ID: 32786155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why Does Prevention of Recurrent Urinary Tract Infection not Result in Less Renal Scarring? A Deeper Dive into the RIVUR Trial.
    Wang HH; Kurtz M; Logvinenko T; Nelson C
    J Urol; 2019 Aug; 202(2):400-405. PubMed ID: 31026216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infections in children.
    Keren R; Chan E
    Pediatrics; 2002 May; 109(5):E70-0. PubMed ID: 11986476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study.
    Keren R; Carpenter MA; Hoberman A; Shaikh N; Matoo TK; Chesney RW; Matthews R; Gerson AC; Greenfield SP; Fivush B; McLurie GA; Rushton HG; Canning D; Nelson CP; Greenbaum L; Bukowski T; Primack W; Sutherland R; Hosking J; Stewart D; Elder J; Moxey-Mims M; Nyberg L
    Pediatrics; 2008 Dec; 122 Suppl 5(Suppl 5):S240-50. PubMed ID: 19018048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.
    McShane LM; Rothmann MD; Fleming TR
    Clin Trials; 2023 Aug; 20(4):341-350. PubMed ID: 37095696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.
    Schnell PM; Müller P; Tang Q; Carlin BP
    Clin Trials; 2018 Feb; 15(1):75-86. PubMed ID: 29035083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of subgroup identification methods for differential treatment effect: Performance metrics and recommendations.
    Alemayehu D; Chen Y; Markatou M
    Stat Methods Med Res; 2018 Dec; 27(12):3658-3678. PubMed ID: 28629264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?
    Zhao B; Ivanova A; Shaikh N
    Res Sq; 2023 Aug; ():. PubMed ID: 37693511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Reanalysis of the RIVUR Trial Using a Risk Classification System.
    Wang ZT; Wehbi E; Alam Y; Khoury A
    J Urol; 2018 Jun; 199(6):1608-1614. PubMed ID: 29198997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antimicrobial prophylaxis in the management of children with vesicoureteral reflux--the RIVUR study outcomes.
    Mathews R; Mattoo TK
    Adv Chronic Kidney Dis; 2015 Jul; 22(4):325-30. PubMed ID: 26088078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    Ngo D; Baumgartner R; Mt-Isa S; Feng D; Chen J; Schnell P
    PLoS One; 2020; 15(2):e0229336. PubMed ID: 32101562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Top-Down versus Bottom-Up Approach in Children Presenting with Urinary Tract Infection: Comparative Effectiveness Analysis Using RIVUR and CUTIE Data.
    Scott Wang HH; Cahill D; Panagides J; Logvinenko T; Nelson C
    J Urol; 2021 Nov; 206(5):1284-1290. PubMed ID: 34181468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A promising subgroup identification method based on a genetic algorithm for censored survival data.
    Zhao L; Zhang W; Wu Y; Cao L; Wang L; Li K
    J Biopharm Stat; 2024 Jan; 34(1):55-77. PubMed ID: 36727221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.